Feedback

Suicidal thoughts and behaviors associated with fluoroquinolone antibiotics: a real-world pharmacovigilance analysis

Affiliation
Department of Pharmacy ,Xiamen Cardiovascular Hospital of Xiamen University ,School of Medicine ,Xiamen University ,Xiamen ,China
Yang, Lijuan;
Affiliation
Department of Pharmacy ,Xiamen Cardiovascular Hospital of Xiamen University ,School of Medicine ,Xiamen University ,Xiamen ,China
Chen, Congqin;
Affiliation
Department of Pharmacy ,Xiamen Cardiovascular Hospital of Xiamen University ,School of Medicine ,Xiamen University ,Xiamen ,China
Ding, Lingqing;
Affiliation
Department of Pharmacy ,Xiamen Cardiovascular Hospital of Xiamen University ,School of Medicine ,Xiamen University ,Xiamen ,China
Lu, Tingting;
Affiliation
Department of Pharmacy ,Xiamen Cardiovascular Hospital of Xiamen University ,School of Medicine ,Xiamen University ,Xiamen ,China
Li, Xiwen;
Affiliation
Department of Pharmacy ,Xiamen Cardiovascular Hospital of Xiamen University ,School of Medicine ,Xiamen University ,Xiamen ,China
Xiao, Jie

Objective This study aimed to systematically and scientifically investigate the potential associations between the use of fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, norfloxacin, and delafloxacin) and suicidal thoughts and behaviors using data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods The FAERS database was queried from the first quarter of 2004 to the fourth quarter of 2023. Disproportionality analysis was conducted using the reporting odds ratio (ROR) and empirical Bayes geometric mean (EBGM). Results A total of 737 cases of suicidal thoughts and behaviors associated with fluoroquinolones (FQs) were reported in the FAERS database during the study period. Overall, FQs did not demonstrate a disproportionate increase in overall cases of suicidal thoughts and behaviors (ROR: 0.74, 95% CI: 0.69–0.79, P < 0.001; EBGM05: 0.69). Stratified analyses revealed no safety signals for suicidal thoughts and behaviors associated with FQs in either females or males. However, subgroup analyses by age groups demonstrated slightly elevated RORs for suicidal thoughts and behaviors in the <18 years age group (ROR: 1.51, 95% CI: 1.05–2.19, P = 0.03) and the 18–24 years age group (ROR: 2.31, 95% CI: 1.75–3.06, P < 0.001), although the EBGM05s values remained below two in both populations. No significant safety signals were observed in the other age groups. Conclusion The analysis of reported cases of suicidal thoughts and behaviors in the FAERS database does not indicate an overall safety signal associated with fluoroquinolones (FQs) at present. Subgroup analysis revealed a slight increase in the RORs for suicidal thoughts and behaviors in the <18 years and the 18–24 years age group; however, no significant safety signal was detected based on the EBGM05s in these populations. Further comprehensive and prospective studies are necessary to confirm and validate these findings.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2025 Yang, Chen, Ding, Lu, Li and Xiao.

Use and reproduction: